RNA Processing and Post-Transcriptional Regulation

By /

Chapter 1: Evolutionary and Compartmental Foundations of RNA Processing

In living systems, the structural compartmentalisation of transcription and translation represents one of the most fundamental evolutionary distinctions between prokaryotes and eukaryotes.

1.1 Prokaryotic Simultaneous Co-transcriptional Translation

  • Compartmentalisation: Lacking a membrane-bound nucleus, prokaryotes transcribe genomic DNA directly within the nucleoid region, which is in direct contact with the cytoplasm.
  • Kinetics: Ribosomes initiate translation on the 5′ end of nascent messenger RNA (mRNA) transcripts as soon as the ribosome-binding site (Shine-Dalgarno sequence) emerges from the RNA polymerase elongation channel.
  • RNA Modification: Because translation occurs simultaneously with transcription, prokaryotic mRNAs undergo very little or no chemical modification after synthesis. They are typically short-lived and degraded rapidly without undergoing processing such as capping, splicing, or polyadenylation.

1.2 Eukaryotic Spatial and Temporal Segregation

  • Compartmentalisation: Eukaryotic genomes are enclosed within the nuclear membrane. Transcription takes place exclusively in the nucleus, whereas translation occurs in the cytosol (or on the rough endoplasmic reticulum).
  • Processing Requirement: Primary transcripts (pre-mRNAs) must undergo extensive chemical and structural processing before being exported from the nucleus. This processing includes:
    • 5′-Capping: Addition of a 7-methylguanosine cap to prevent 5′ → 3′ degradation.
    • 3′-Polyadenylation: Cleavage of the transcript and addition of a template-independent poly(A) tail to prevent 3′ → 5′ degradation and facilitate cytosolic export.
    • Intron Splicing: Excising non-coding introns and joining exons to generate a continuous open reading frame.
  • Organellar and Transfer RNA Modification: Eukaryotes extensively modify organellar transcripts (mitochondrial and chloroplast RNAs), transfer RNAs (pre-tRNAs), and ribosomal RNAs (pre-rRNAs) through complex cleavage, trimming, and base modification networks.
Prokaryotic vs. Eukaryotic Gene Expression Architecture PROKARYOTES (Simultaneous Translation) DNA mRNA Ribosome Active Polypeptide EUKARYOTES (Spatially Segregated) [ NUCLEUS ] DNA Capped & Spliced Mature mRNA Pore [ CYTOSOL ] Ribosome Translation

Chapter 2: Eukaryotic pre-mRNA 5'-Capping

5′-capping is the first modification made to RNA Polymerase II-transcribed pre-mRNA. This reaction occurs co-transcriptionally within the nucleus as soon as the first 25 to 30 nucleotides of the nascent RNA are synthesized and emerge from the exit tunnel of the transcription complex.

2.1 The Three-Step Enzymatic Cascade

The capping process is catalysed by a dimeric capping enzyme that associates directly with the phosphorylated Carboxyl-Terminal Domain (CTD) of RNA Polymerase II (specifically when the CTD heptad repeats are phosphorylated at the Ser5 position). The three sequential enzymatic activities are:

  • RNA Triphosphatase: Removes the terminal γ-phosphate from the 5′ end of the nascent transcript, converting a 5′-triphosphate (5′-pppRNA) to a 5′-diphosphate (5′-ppRNA).
  • RNA Guanylyltransferase: Catalyses a nucleophilic attack by the β-phosphate of the 5′-diphosphate on the α-phosphate of a GTP molecule. This transfers a GMP moiety to the 5′ end of the RNA, establishing a unique, highly stable 5′-to-5′ triphosphate linkage (G(5′)ppp(5′)RNA) and releasing pyrophosphate (PPi).
  • Guanine-N7 Methyltransferase: Transfers a methyl group (-CH3) from S-adenosylmethionine (SAM / S-Ado-Met) to the N7 position of the newly attached guanine residue, creating the Cap 0 structure (m7G(5′)ppp(5′)RNA).
5'-Capping Enzymatic Cascade 1. RNA Triphosphatase Removes gamma-phosphate 2. RNA Guanylyltransferase Transfers GMP from GTP; releases PPi 3. Guanine-N7 Methyltransferase Adds methyl from S-Ado-Met 5′ ppp-N-p-N-p-N... 3′ ↓ (Triphosphatase → Guanylyltransferase) 5′ G(5′)ppp(5′)-N-p-N... 3′ ↓ (N7 Methyltransferase → CAP 0)

2.2 Cap Methylation Variants (Cap 0, Cap 1, Cap 2)

Depending on the organism and cell type, additional methylations can occur on the ribose sugars of the first and second nucleosides of the transcript:

  • Cap 0: Present in all eukaryotes. Only the terminal guanine is methylated at the N7 position.
  • Cap 1: Found predominantly in multicellular organisms. In addition to the m7G cap, a methyl group is added to the 2′-OH position of the ribose sugar of the first nucleotide adjacent to the cap (converting O-methyl at C′2). If this first nucleotide is adenine, an additional methyl group can be added to the N6 position (m6A).
  • Cap 2: Found in higher eukaryotes. Along with the Cap 1 modifications, a methyl group is added to the 2′-OH position of the ribose sugar of the second nucleotide.

2.3 Biological Functions of the 5'-Cap

The 5′-cap acts as an indispensable, evolutionarily conserved molecular hub that recruits specific proteins to complete the following tasks:

  • Protection against Degradation: Blocks 5′ → 3′ exoribonucleases (such as Xrn1) by masking the 5′ end of the transcript.
  • Nuclear Export: Recruits the heterodimeric Cap-Binding Complex (CBC), which coordinates docking with nuclear pore proteins for transit into the cytosol.
  • Splicing Promotion: Enhances excision of the first intron of the pre-mRNA by recruiting spliceosomal components to the 5′ end.
  • Translation Initiation: In the cytoplasm, the eukaryotic initiation factor eIF4E binds the cap, recruiting the eIF4F complex and the 40S ribosomal subunit for cap-dependent translation.
  • Cytoplasmic Capping: Although historically believed to occur exclusively in the nucleus, capping enzymes have been identified operating on cytoplasmic pools of mRNA in mammalian cells and parasites such as Trypanosoma.

Chapter 3: Pre-mRNA Splicing and the Spliceosome Architecture

Most eukaryotic protein-coding genes contain non-coding intervening sequences (introns) interspersed between coding sequences (exons). Pre-mRNA splicing is the precise molecular process of removing introns and ligating exons together to form a continuous open reading frame.

3.1 Splice Site Consensus Sequences

The boundaries of introns are defined by short, conserved sequence motifs recognized by the splicing machinery:

  • 5′ Splice Site (Donor Site): Located at the boundary between the upstream exon and the intron. It possesses a highly conserved invariant dinucleotide: 5′ - AG / GURAGU - 3′ (where R is a purine).
  • Branch Point Sequence (BPS): Located 18 to 40 nucleotides upstream of the 3′ splice site. It contains an invariant adenine nucleotide embedded within a conserved degenerate sequence: 5′ - CURAY - 3′.
  • Polypyrimidine Tract: A stretch of 10 to 15 pyrimidines (cytosines and uracils) situated between the branch point and the 3′ splice site, which recruits auxiliary splicing factors.
  • 3′ Splice Site (Acceptor Site): Located at the downstream boundary of the intron. It possesses an invariant dinucleotide: 5′ - YAG / G - 3′ (where Y is a pyrimidine).

3.2 The Two Transesterification Reactions

Splicing proceeds strictly via two sequential, energy-neutral transesterification reactions that preserve the total number of phosphodiester bonds:

  1. First Transesterification (Lariat Formation): The 2′-OH group of the invariant branch point adenine makes a nucleophilic attack on the phosphodiester bond at the 5′ splice site. This cleaves the sugar-phosphate backbone at the 5′ exon-intron junction and simultaneously forms an unusual 2′-5′ phosphodiester bond, creating a branched lariat intermediate (loop structure) and releasing Exon 1 with a free 3′-OH group.
  2. Second Transesterification (Exon Ligation): The newly freed 3′-OH group of Exon 1 acts as a nucleophile, attacking the phosphodiester bond at the 3′ splice site. This joins Exon 1 and Exon 2 in a standard 5′-3′ phosphodiester linkage and releases the intron in its excised lariat form, which is subsequently debranched and degraded in the nucleus.
Two-Step Transesterification Mechanism of SplicingStep 1: Branch Point Nucleophilic Attack Exon 1 Intron (5′ GU ... A ... AG 3′) Exon 2 2′-OH of Branch Point 'A' attacks 5′ splice siteStep 2: Lariat Intermediate & Exon Ligation Exon 1 (Free 3′-OH) Intron Lariat (2′-5′ bond) Exon 2

3.3 The Spliceosome Machinery (snRNPs)

Nuclear pre-mRNA splicing is mediated by a massive dynamic ribonucleoprotein complex known as the spliceosome, which assembles de novo on each intron. It is composed of five core small nuclear RNAs (snRNAs: U1, U2, U4, U5, and U6) complexed with specific proteins to form small nuclear ribonucleoproteins (snRNPs):

snRNPPrimary RNA/Protein CompositionKey Biochemical Functions in Splicing
U1 snRNPU1 snRNA + Sm proteinsInitial recognition and binding to the 5′ splice site via precise base-pairing.
U2 snRNPU2 snRNA + Sm proteinsBinds to the branch point sequence, bulging out the invariant adenosine to expose its 2′-OH group.
U4/U6.U5 Tri-snRNPU4, U5, U6 snRNAs + proteinsBinds the assembled complex; U5 holds the exons in proximity, while U6 displaces U1 to form the active catalytic core.

Chapter 4: Alternative Splicing Mechanisms and Transcript Diversity

Alternative splicing is a highly regulated post-transcriptional process that enables a single eukaryotic gene to code for multiple distinct protein isoforms, vastly expanding proteomic complexity without increasing genome size.

4.1 Major Modes of Alternative Splicing

Through differential selection of splice sites, pre-mRNAs can be processed via several primary pathways:

  • Exon Skipping (Cassette Exon): The most common mode in mammals; a specific exon is either included in the mature mRNA or omitted along with its flanking introns.
  • Alternative 5′ Splice Site: Selection of different 5′ donor sites alters the boundary of an exon, changing its length.
  • Alternative 3′ Splice Site: Selection of different 3′ acceptor sites alters the boundary of the downstream exon.
  • Mutually Exclusive Exons: One of two exons is retained in the mRNA, but never both simultaneously.
  • Intron Retention: An intron remains unspliced and is retained in the mature mRNA transcript, often introducing a premature stop codon.

4.2 Splicing Regulatory Factors (SR Proteins and hnRNPs)

Alternative splicing decisions are controlled by trans-acting RNA-binding proteins that recognize specific cis-acting regulatory sequences within exons and introns (Exonic/Intronic Splicing Enhancers [ESEs/ISEs] and Silencers [ESSs/ISSs]):

  • SR Proteins (Serine/Arginine-rich proteins): Generally function as splicing activators. They bind to ESEs and promote the recruitment of spliceosomal components (such as U1 snRNP and U2AF) to weak splice sites.
  • hnRNPs (Heterogeneous nuclear ribonucleoproteins): Generally function as splicing repressors. They bind to ESSs or silencer sequences, sterically blocking spliceosomal assembly or compacting the RNA to hide splice sites.

Chapter 5: 3'-End Processing: Cleavage and Polyadenylation

The 3′ end of most eukaryotic eukaryotic pre-mRNAs is generated not by transcription termination alone, but through a coupled two-step enzymatic process involving site-specific endonucleolytic cleavage followed by template-independent polyadenylation.

5.1 Consensus Signal Sequences

Accurate 3′-end processing requires specific cis-acting sequence elements located in the 3′ untranslated region (3′-UTR) of the pre-mRNA:

  • The Polyadenylation Signal (Hexamer): The highly conserved consensus sequence 5′ - AAUAAA - 3′ (or close variants like AUUAAA), located 10 to 30 nucleotides upstream of the cleavage site.
  • The Downstream Element (DSE): A variable GU-rich or U-rich sequence located 20 to 40 nucleotides downstream of the cleavage site.
  • The Cleavage Site: Typically occurs at an unpaired adenosine residue situated between the hexamer signal and the downstream element.

5.2 Multi-Protein Processing Machinery

The core multi-protein complexes required for cleavage and polyadenylation include:

  • CPSF (Cleavage and Polyadenylation Specificity Factor): A multi-subunit complex that binds directly to the upstream AAUAAA hexamer.
  • CstF (Cleavage Stimulation Factor): Binds to the downstream GU-rich element (DSE). Cooperation between CPSF and CstF loops the RNA to define the cleavage site.
  • CF I and CF II (Cleavage Factors I and II): Endonucleases that execute the precise cleavage of the pre-mRNA transcript.
  • PAP (Poly(A) Polymerase): A template-independent polymerase that adds a tail of 200 to 250 adenosine residues onto the newly generated 3′-OH end, assisted by Poly(A)-Binding Protein Nuclear 1 (PABPN1) to regulate tail length.
3'-End Cleavage and Polyadenylation Mechanism pre-mRNA AAUAAA GU-Rich DSE Cleavage Site CPSF CstFResult: Cleavage & Poly(A) Addition poly(A) tail (~200-250 A's)

Chapter 5: The Spliceosome Assembly Cascade

The excision of nuclear introns is catalysed by the spliceosome, a dynamic 60S macromolecular machine composed of five small nuclear RNAs (snRNAs)—U1, U2, U4, U5, and U6—which associate with specific proteins to form small nuclear ribonucleoprotein particles (snRNPs).

5.1 Stepwise Assembly of snRNPs

The assembly of the spliceosome on a pre-mRNA transcript occurs through a highly regulated, hierarchical pathway:

  • Commitment (E) Complex:
    • U1 snRNP binds to the 5′ splice site via base-pairing between its snRNA and the pre-mRNA consensus donor sequence.
    • Branch point binding protein (BBP) binds directly to the branch-point adenine.
    • The heterodimer U2 Auxiliary Factor (U2AF) binds to the polypyrimidine tract (Yn) and the 3′ splice site AG dinucleotide.
    • This initial assembly occurs in an ATP-independent manner and commits the transcript to the splicing pathway.
  • Pre-spliceosome (A) Complex:
    • U2 snRNP is recruited to the branch point.
    • This step requires ATP hydrolysis to remodel the RNA. U2 snRNA base-pairs with the branch point sequence, causing the branch-point adenine to bulge out, exposing its 2′-OH group for nucleophilic attack. BBP is displaced during this remodeling step.
  • Pre-catalytic Spliceosome (B1) Complex:
    • The pre-assembled [U4/U6.U5] tri-snRNP is recruited to the A complex.
    • Within the tri-snRNP, U4 and U6 snRNAs are held together in an inactive state by extensive base-pairing, while U5 snRNP acts as a scaffold.
  • Activated Spliceosome (B2) Complex:
    • The spliceosome undergoes major conformational rearrangements that require ATP hydrolysis.
    • U1 snRNP is released from the 5′ splice site.
    • U4 snRNP is unwound and ejected from the complex. This frees U6 snRNA, allowing it to base-pair with both the 5′ splice site and U2 snRNA, forming the active catalytic core.
  • Catalytic (C) Complex:
    • With the active site formed by the U2/U6 complex, the first transesterification reaction takes place, yielding the lariat intermediate.
    • The spliceosome undergoes further structural changes, aligning the free 3′-OH of Exon 1 with the 3′ splice site to execute the second transesterification reaction, which ligates the exons and releases the lariat.
Spliceosome Assembly Pathway (E to C Complexes) E Complex (Commitment) 5′ [U1] == GU ... [A] ... Y_n == AG == 3′ + U2 snRNP (ATP) A Complex (Pre-spliceo) 5′ [U1][U2] = GU ... [A*] ... Y_n == AG == 3′ + Tri-snRNP [U4/U6.U5] (ATP) B1 Complex (Pre-catalytic) 5′ [U4/U6.U5][U1][U2] = GU ... [A*] ... AG == 3′ Release U1, U4 (ATP) → Active Core C Complex (Catalytic) 5′ [Exon 1-OH] Lariat Intron-[Exon 2] 3′

5.2 Splicing Selection: Exon Definition vs. Intron Definition

The spliceosome must locate splice sites across transcripts that can vary significantly in length. Organisms use two distinct mechanism pathways to define splice sites:

  • Exon Definition:
    • Occurrence: Common in vertebrates, which typically have short exons (100 to 300 bp) separated by long introns (often tens of kilobases).
    • Mechanism: The splicing machinery initially recognizes and assembles around the exon rather than the intron. Splicing factors span the exon, pairing the 3′ splice site complex at the upstream end of the exon with the 5′ splice site complex at the downstream end. Once the exons are defined, the machinery is remodeled to splice out the flanking introns.
  • Intron Definition:
    • Occurrence: Common in lower eukaryotes (such as yeasts) and some plants, which typically have long exons separated by short, highly conserved introns.
    • Mechanism: The splicing machinery spans the intron directly, recruiting U1 to the 5′ splice site and U2 to the 3′ splice site of the same intron.

5.3 Splicing Specificity and Regulation: Enhancers and Silencers

Splice site selection is regulated by cis-acting sequences that recruit trans-acting proteins to either activate or repress nearby splice sites:

  • Splicing Enhancers:
    • Exonic Splicing Enhancers (ESEs) and Intronic Splicing Enhancers (ISEs) are regulatory sequences that promote splice site recognition.
    • They are recognized and bound by SR proteins (proteins rich in Serine and Arginine residues). SR proteins use their RNA-recognition motifs (RRMs) to bind the enhancer and their RS domains to recruit and stabilize U1 snRNP at the 5′ splice site and U2AF at the 3′ splice site.
  • Splicing Silencers:
    • Exonic Splicing Silencers (ESSs) and Intronic Splicing Silencers (ISSs) are regulatory sequences that repress splice site recognition.
    • They are bound by Heterogeneous Nuclear Ribonucleoproteins (hnRNPs). When bound, hnRNPs sterically block splice site recognition or prevent the assembly of the active spliceosome.

Chapter 6: Regulated Alternative Splicing: Drosophila Sex Determination

Alternative splicing is a key eukaryotic regulatory mechanism that allows a single gene to encode multiple distinct protein isoforms. The somatic sex determination cascade in Drosophila melanogaster is one of the most thoroughly understood genetic examples of regulated alternative splicing.

6.1 Sensing the Chromosome-to-Autosome (X:A) Ratio

In Drosophila, sex is determined by the ratio of X-chromosomes to sets of autosomes (X:A ratio):

  • Females (X:A = 1.0): Possess two X-chromosomes. This double dose of X-linked transcription factors activates the transient expression of the Sex-lethal (Sxl) protein during early embryogenesis.
  • Males (X:A = 0.5): Possess only one X-chromosome. The single dose of these transcription factors is insufficient to activate early Sxl expression, so no early Sxl protein is produced.

6.2 The Splicing Cascade: Sxl, Tra, and Dsx

Once established during early embryogenesis, the sex determination signal is maintained throughout development by a hierarchical cascade of alternative splicing events:

  • Step 1: Sex-lethal (sxl) Splicing
    • Male Pathway: In the absence of early Sxl protein, default splicing of the sxl pre-mRNA includes Exon 3. Exon 3 contains an in-frame UAG stop codon, which leads to translation of a short, non-functional Sxl peptide.
    • Female Pathway: Early Sxl protein acts as a splicing repressor. It binds to a pyrimidine-rich tract at the 3′ splice site of the intron upstream of Exon 3, blocking the recruitment of U2AF. This forces the spliceosome to skip Exon 3 and splice Exon 2 directly to Exon 4. This alternative splicing event produces a functional, full-length Sxl protein, establishing a positive feedback loop that maintains sxl expression in its active state.
  • Step 2: Transformer (tra) Splicing
    • Male Pathway: Without functional Sxl protein, default splicing of the tra pre-mRNA includes Exon 2. Exon 2 contains an in-frame stop codon, resulting in a non-functional Tra peptide.
    • Female Pathway: Functional Sxl protein binds to the default 3′ splice site of the intron upstream of Exon 2, blocking its use. This forces the spliceosome to use a weaker, alternative 3′ splice site located further downstream, which splices out the stop codon in Exon 2. This alternative splicing event produces a functional, active Tra protein.
  • Step 3: Doublesex (dsx) Splicing
    • Male Pathway: In the absence of functional Tra protein, the default splicing of dsx pre-mRNA excludes Exon 4 and joins Exon 3 directly to Exon 5. This produces the Male Dsx protein (550 amino acids), a transcription factor that represses genes required for female development and activates male-specific genes.
    • Female Pathway: Tra is a splicing activator. Along with the constitutively expressed protein Tra2, Tra binds to an exonic splicing enhancer (ESE) in Exon 4. This recruits the spliceosome to the weak 3′ splice site of Exon 4, causing it to be included in the final transcript, which terminates with a poly(A) site in Exon 4. This alternative splicing event produces the Female Dsx protein (430 amino acids), a transcription factor that represses genes required for male development and activates female-specific genes.
Drosophila Somatic Sex Determination Cascade MALE (X:A = 0.5) FEMALE (X:A = 1.0) Sxl Splicing: Default: Exon 3 included (Stop codon) → Non-functional Sxl Protein Sxl represses Exon 3 (Skipped) → Functional Sxl Protein Tra Splicing: Default: Exon 2 included (Stop codon) → Non-functional Tra Protein Sxl blocks default 3′SS; alternative used → Functional Tra Protein Dsx Splicing: Default: Exon 4 skipped (Exons 1,2,3,5,6) → Male Dsx (550 aa) → Male Phenotype Tra + Tra2 activate Exon 4 3′SS → Female Dsx (430 aa) → Female Phenotype

Chapter 7: Specialized Splicing Pathways: Trans-Splicing

While conventional splicing (cis-splicing) joins exons within a single continuous pre-mRNA transcript, trans-splicing ligates exons from two entirely separate RNA molecules.

7.1 Spliced Leader (SL) RNA and the Y-Shaped Branch Intermediate

Trans-splicing is highly widespread in organisms such as trypanosomes (e.g., Trypanosoma brucei) and nematodes (e.g., C. elegans).

  • SL RNA Structure: The donor RNA molecule is called the Spliced Leader (SL) RNA. It is a small transcript that contains a highly conserved, capped 5′ exon (the SL Exon) and a 3′ intron portion that ends with a conserved 5′ splice site donor (GU).
  • Chemistry and the Y-Intermediate: Splicing proceeds via two successive transesterification reactions similar to cis-splicing. However, because the donor and acceptor exons reside on separate molecules:
    • The first transesterification occurs when the 2′-OH of the branch-point adenine in the target pre-mRNA attacks the 5′ splice site of the SL RNA.
    • This joins the 5′ end of the SL intron to the branch-point adenine, forming a Y-shaped branched RNA intermediate rather than a closed lariat loop.
    • The second transesterification joins the SL Exon to the 5′ end of the target Exon 2, producing a mature chimeric mRNA.
Trans-Splicing Mechanism & Y-Intermediate SL RNA: 5′ [Cap]-SL GU Pre-mRNA: A AG Exon 2 Reaction Products: 1. Processed Chimeric mRNA: 5′ [Cap]-SL Exon 2 3′2. Y-Shaped Intron Product: A SL Intron Residual ↑

7.2 Intragenic vs. Intergenic Trans-Splicing

  • Intragenic Trans-Splicing: Occurs when exons from separate pre-mRNAs transcribed from the same gene locus are joined together, often yielding transcripts with duplicated exon sequences.
  • Intergenic Trans-Splicing: Occurs when exons transcribed from completely different gene loci are joined, creating unique chimeric proteins.

Chapter 8: RNA Editing (Substitution and Insertion-Deletion)

RNA editing is a post-transcriptional process that alters the nucleotide sequence of an RNA molecule so that the mature, translated mRNA differs from the sequence encoded in the genomic DNA.

8.1 Site-Specific Substitution Editing

Site-specific substitution editing involves the precise chemical deamination of specific bases within a transcript.

  • C → U Editing of Apolipoprotein B (ApoB):
    • The Gene: A single genomic locus encodes Apolipoprotein B, which is essential for lipid transport.
    • Liver Expression: In liver cells, the transcript remains unedited. Codon 2153 is read as CAA, which encodes the amino acid Glutamine (Gln). This leads to the translation of the full-length ApoB-100 protein (4563 amino acids).
    • Intestinal Expression: In intestinal cells, the enzyme cytidine deaminase is active. It binds to a specific mooring sequence upstream of codon 2153 and deaminates the cytosine at position 2153 to a uracil, converting the CAA codon to a UAA stop codon. This leads to translation of the truncated ApoB-48 protein (2152 amino acids), which lacks the low-density lipoprotein (LDL) receptor-binding domain and is tailored for absorbing dietary lipids.
  • A → I Editing by ADARs:
    • Mechanism: Adenosine Deaminases Acting on RNA (ADARs) bind to double-stranded regions of pre-mRNA and deaminate specific adenosine residues to inosine (I).
    • Translation: Inosine is structurally similar to guanosine. During translation, the ribosome reads inosine as Guanosine (G), which can alter the amino acid sequence of the encoded protein (e.g., the glutamate receptor channel in mammalian brains).
C-to-U Deamination of Apolipoprotein B (ApoB) Liver Cells (Unedited) 5′ ... CAA [Codon 2153 - Gln] ... 3′ → ApoB-100 (4563 aa) Long, multi-functional lipid carrier protein. Intestinal Cells (Cytidine Deaminase Active) 5′ ... UAA [Codon 2153 - Stop] ... 3′ → ApoB-48 (2152 aa) Truncated, specialized dietary lipid absorber. A-to-I Editing by ADARs: Pre-mRNA dsRNA regions → Adenosine → Inosine (I) Ribosome reads Inosine as Guanosine (G). Alters target amino acid sequences in neural proteins (e.g., glutamate receptors).

8.2 Insertion-Deletion Editing

Insertion-deletion editing involves the template-directed insertion or deletion of uridine (U) residues within mitochondrial transcripts in kinetoplastid protozoans (such as Trypanosoma).

  • The 20S Editosome: A large macromolecular complex (the 20S editosome) catalyses these editing events. It contains endonucleases, Terminal Uridylyl Transferase (TUTase), uridylate-specific exonucleases, and RNA ligases.
  • Guide RNAs (gRNAs): Small, mitochondrial-encoded RNAs that act as templates to direct editing. A gRNA consists of three domains:
    • 5′ Anchor Region: Base-pairs with the pre-edited mRNA directly upstream of the site to be edited.
    • Central Domain: Contains the template sequence. It is partially complementary to the pre-edited mRNA but contains extra adenosine (A) or guanosine (G) residues that direct the insertion or deletion of uridines in the mRNA.
    • 3′ Poly-U Tail: Stabilizes the editing complex.
  • Step-by-Step Mechanism:
    • Annealing: The gRNA anchor region base-pairs with the target pre-mRNA.
    • Cleavage: An endonuclease within the editosome cleaves the pre-mRNA backbone at the first mismatch site adjacent to the anchor.
    • Modification:
      • U-Insertion: TUTase adds one or more U residues to the 3′-OH of the upstream pre-mRNA fragment, using UTP as a substrate, until they can base-pair with the template bases in the gRNA.
      • U-Deletion: If the gRNA template lacks complementary bases for U residues in the pre-mRNA, a uridylate-specific exonuclease removes the unpaired U residues from the cleaved pre-mRNA fragment.
    • Ligation: An RNA ligase within the editosome seals the phosphodiester backbone, joining the edited pre-mRNA fragments together.
Insertion-Deletion Editing Mechanism (20S Editosome) 1. Annealing & Endonucleolytic Cleavage Pre-mRNA: 5′ ... C-G-A-C-G ... 3′ | gRNA Anchor cuts mismatch 2. TUTase Uridylation (U-Insertion) TUTase adds U residues using UTP to match gRNA template 3. RNA Ligase Sealing & Final Product Edited mRNA: 5′ ... C-U-U-U-G-A-C-G ... 3′ Fully complementary to guide RNA sequence.

Chapter 9: Ribosomal RNA (pre-rRNA) Processing

Ribosomal RNAs are synthesized as large precursor transcripts that must be chemically modified and cleaved to produce mature, functional rRNAs.

9.1 Eukaryotic 45S pre-rRNA Processing

In eukaryotes, three of the four core rRNAs (18S, 5.8S, and 28S) are transcribed by RNA Polymerase I in the nucleolus as a single 45S pre-rRNA precursor transcript (approximately 7,500 nucleotides long). The fourth rRNA, 5S rRNA, is transcribed independently by RNA Polymerase III in the nucleoplasm and does not undergo significant processing.

  • Chemical Modification: Before cleavage, the 45S pre-rRNA undergoes extensive chemical modification guided by small nucleolar RNAs (snoRNAs), which assemble into snoRNP complexes:
    • C/D Box snoRNAs: Direct site-specific 2′-O-methylation of ribose sugars.
    • H/ACA Box snoRNAs: Direct site-specific pseudouridylation (the isomerization of uridine to pseudouridine, ψ).
  • Cleavage and Trimming: Following modification, a cascade of nucleolytic cleavages by endonucleases and trimming by exonucleases removes the non-coding External Transcribed Spacers (ETS) and Internal Transcribed Spacers (ITS1 and ITS2) to yield mature 18S (small subunit), 5.8S, and 28S (large subunit) rRNAs.
Eukaryotic 45S pre-rRNA Processing 45S Gene Cluster: 18S rDNA ITS1 5.8S rDNA ITS2 28S rDNA RNA Pol I 45S pre-rRNA: 18S rRNA 5.8S rRNA 28S rRNA snoRNA Modification (ψ, Methyl) Modified: *18S* *5.8S* *28S* Cleavage & Trimming Mature: 18S 5.8S 28S

9.2 Prokaryotic 30S pre-rRNA Processing

In eubacteria such as E. coli, ribosomal genes are organized into operons that are transcribed as a single 30S pre-rRNA precursor transcript (approximately 5,500 nucleotides long).

  • Subunit Composition: The 30S precursor contains one copy each of 16S rRNA, 23S rRNA, and 5S rRNA, separated by spacer regions that often contain one or two transfer RNA (tRNA) genes.
  • Primary Cleavage: The double-stranded RNA stems that flank the 16S and 23S sequences are recognized and cleaved by RNase III.
  • Secondary Processing: Additional endonucleases and exonucleases process the remaining fragments:
    • RNase P and RNase E/F cleave downstream spacer sequences.
    • RNase M and other exonucleases trim the precursor RNAs to generate mature 16S, 23S, and 5S rRNAs and active tRNAs.
Prokaryotic 30S pre-rRNA Processing 30S pre-rRNA: 16S rRNA tRNA 23S rRNA 5S rRNA tRNA Primary Cleavage (RNase III) Intermediates: 16S Intermediate 5S Intermediate Trimming (RNase M, P, F) Mature: 16S rRNA 23S rRNA 5S rRNA

Chapter 10: Catalytic Introns (Self-Splicing Ribozymes)

Certain introns can catalyse their own excision without the aid of proteins or the spliceosome. These catalytic RNAs are known as self-splicing introns or ribozymes. They are grouped into two major classes: Group I and Group II.

10.1 Structural and Chemical Comparison

A detailed comparison of the structural features and chemical mechanisms governing Group I and Group II self-splicing introns is provided below:

FeatureGroup I IntronsGroup II Introns
Primary NucleophileExogenous Guanosine (G, GMP, GDP, or GTP)Internal Adenosine (2′-OH group within the intron sequence)
First Step Chemical LinkagePhosphodiester bond between exogenous G and the 5′ end of the intron2′-to-5′ phosphodiester bond forming a lariat structure
Excised Intron StructureLinear RNA (which subsequently undergoes self-cyclization)Lariat RNA (structurally identical to spliceosome-cleaved introns)
OccurrencePre-rRNA of Tetrahymena thermophila, fungal mitochondria, bacteriophagesPlant/fungal organelles, bacteria, archaea
Divalent Metal DependencyRequires divalent cations (usually Mg2+ or Mn2+)Requires divalent cations (usually Mg2+ or Mn2+)

10.2 Splicing Chemistry of Group I and Group II Introns

  • Group I Splicing Pathway:
    • An exogenous guanosine cofactor binds to a conserved guanosine-binding pocket within the folded intron structure.
    • The 3′-OH group of the bound guanosine acts as a nucleophile, attacking the phosphodiester bond at the 5′ splice site. This cleaves the 5′ site and covalently attaches the exogenous guanosine to the 5′ end of the intron.
    • The free 3′-OH group of Exon 1 then attacks the phosphodiester bond at the 3′ splice site, joining the exons and releasing the linear intron.
    • The released linear intron contains a highly reactive 3′-OH group that can attack an internal phosphodiester bond within the intron, releasing a small fragment and forming a stable circular RNA.
  • Group II Splicing Pathway:
    • The 2′-OH group of a conserved internal adenosine residue within the intron acts as a nucleophile, attacking the 5′ splice site.
    • This cleaves the 5′ splice site and forms a lariat intermediate with a 2′-to-5′ phosphodiester linkage.
    • The free 3′-OH group of Exon 1 attacks the 3′ splice site, joining the exons and releasing the intron lariat. This pathway is chemically identical to the spliceosome-catalysed splicing of nuclear pre-mRNA, suggesting that nuclear pre-mRNA splicing evolved from an ancestral Group II self-splicing mechanism.
Group I vs. Group II Self-Splicing Pathways Group I: Exogenous Guanosine-Driven Splicing HO-G (Exogenous Nucleophile) attacks 5′SS 5′ [ Exon 1 ]-p-[ Intron ]-[ Exon 2 ] 3′ Product: Linear Intron released → self-cyclization. Group II: Internal Adenosine-Driven Splicing Internal Branch Point A (2′-OH) attacks 5′SS 5′ [ Exon 1 ]-p-[ Intron ]-[ Exon 2 ] 3′ Product: Lariat Intron released (Spliceosome-identical pathway).

10.3 Mobility Pathways: Homing vs. Retrohoming

Many Group I and Group II introns contain open reading frames (ORFs) that encode multifunctional enzymes, allowing the introns to act as mobile genetic elements:

  • Group I Intron Mobility (Homing):
    • The Enzyme: Encodes a homing endonuclease.
    • Mechanism: The homing endonuclease is expressed and cleaves a highly specific target site in an intron-minus allele of the same gene, generating a double-strand break (DSB). The cell's double-strand break repair machinery uses the intron-containing allele as a template for homologous recombination, copying the Group I intron into the target locus.
  • Group II Intron Mobility (Retrohoming):
    • The Enzyme: Encodes a multifunctional protein with reverse transcriptase (RT), endonuclease, and maturase activities.
    • Mechanism: The expressed intron-encoded protein binds to the excised lariat RNA. This ribonucleoprotein complex recognizes a specific target site in an intron-minus allele. The intron RNA reverse-splices directly into one strand of the target DNA. The endonuclease then cleaves the opposite DNA strand, generating a free 3′-OH primer that the RT domain uses to copy the intron RNA into DNA (target-primed reverse transcription), integrating the intron into the locus.

Chapter 11: Transfer RNA (pre-tRNA) Processing

Transfer RNAs (tRNAs) are synthesized as larger precursor transcripts (pre-tRNAs) that must undergo a series of precise enzymatic cleavage, trimming, addition, and base modification steps to become translationally active.

11.1 The Stepwise Processing Pathway

The maturation of eukaryotic and prokaryotic pre-tRNAs occurs through the following sequential steps:

  • 5′ End Cleavage by RNase P:
    • The extra 5′ leader sequence is removed by a single endonucleolytic cleavage catalysed by Ribonuclease P (RNase P).
    • RNase P is a conserved ribonucleoprotein complex. In both prokaryotes and eukaryotes, the RNA component of the enzyme contains the active catalytic site (making RNase P a ribozyme), while the protein subunits stabilize its structure and assist in substrate binding.
  • 3′ End Trimming and CCA Addition:
    • The extra 3′ trailer sequence is removed by endonucleases and exonucleases, generating a free 3′-OH group.
    • Because the functional 5′-CCA-3′ amino-acid attachment sequence is not encoded in eukaryotic tRNA genes, it must be added post-transcriptional to the 3′ end. This is catalysed by the template-independent enzyme tRNA nucleotidyltransferase, which uses CTP and ATP as substrates to synthesize the CCA-3′ terminus.
  • Chemical Base Modifications:
    • Mature tRNAs contain a high density of modified bases that stabilize their tertiary structure and optimize codon-anticodon pairing on the ribosome:
      • Methylation: Conversion of bases to methylguanosine or methyladenosine.
      • Reduction: Conversion of uridine to dihydrouridine (D), which destabilizes stacking interactions and increases local flexibility.
      • Isomerization: Conversion of uridine to pseudouridine (ψ), which stabilizes local folding.
      • Deamination: Conversion of adenosine to inosine (I) in the anticodon loop, facilitating wobble base-pairing.
tRNA Processing Pathway 1. Pre-tRNA Precursor 5′ [5′ Leader] === [ folded pre-tRNA ] === [3′ Trailer]-OH 3′ RNase P & Nucleases Trim Ends 2. End-Trimmed tRNA 5′ [ folded tRNA ] 3′-OH tRNA Nucleotidyltransferase (Adds CCA-3′) 3. Mature Modified tRNA 5′ [ folded tRNA ]-C-C-A 3′ + Base Modifications

11.2 Non-Spliceosomal pre-tRNA Intron Splicing

Some eukaryotic pre-tRNAs contain a small intron located in the anticodon loop. These introns are spliced out via an enzymatic pathway that does not involve the spliceosome:

  • Endonucleolytic Cleavage: A membrane-associated, heterotetrameric tRNA endonuclease cleaves both the 5′ and 3′ splice sites of the pre-tRNA intron. This cleavage leaves a 2′,3′-cyclic phosphate group on the 3′ end of the upstream exon and a 5′-OH group on the downstream exon.
  • Activation:
    • A kinase transfers a phosphate group from ATP to the 5′-OH group of the downstream exon, creating a reactive 5′-phosphate.
    • A cyclic phosphodiesterase hydrolyses the 2′,3′-cyclic phosphate on the upstream exon, converting it to a 2′-phosphate and exposing a free 3′-OH group.
  • Ligation: An RNA ligase uses ATP to join the 3′-OH of the upstream exon to the 5′-phosphate of the downstream exon, creating a standard phosphodiester bond that contains an adjacent 2′-phosphate group.
  • Dephosphorylation: A dedicated phosphotransferase transfers the 2′-phosphate to an acceptor molecule, yielding a mature, continuous tRNA loop.
tRNA Endonuclease/Ligase Splicing Pathway 1. Endonuclease Cleavage Products: 5′ exon with 2′,3′-cyclic P + 5′-OH downstream exon 2. Kinase & Phosphodiesterase Activation Creates reactive 5′-phosphate and 2′-phosphate intermediates 3. RNA Ligase Joining Joins 3′-OH to 5′-phosphate (contains adjacent 2′-P) 4. Dephosphorylation → Mature tRNA Removes 2′-P to yield continuous mature tRNA loop

Chapter 12: mRNA Degradation and Quality Control Surveillance

The steady-state concentration of eukaryotic and prokaryotic transcripts depends on both their rate of transcription and their rate of degradation.

12.1 Prokaryotic mRNA Degradation

Bacterial mRNAs are short-lived, with an average half-life of only 1.5 to 3 minutes.

  • The Degradosome: Bacterial mRNA degradation occurs in a 3′ → 5′ direction and is carried out by a multi-protein complex called the degradosome.
  • Subunit Composition: The E. coli degradosome is composed of:
    • RNase E: A large endonuclease that cleaves single-stranded, AU-rich regions within target mRNAs.
    • Polynucleotide Phosphorylase (PNPase): A 3′ → 5′ exoribonuclease.
    • RNA Helicase (RhlB): Unwinds secondary structure stem-loops to allow PNPase access.
    • Enolase: A glycolytic enzyme whose structural role in degradation is not yet fully understood.

12.2 Eukaryotic mRNA Degradation Pathways

Eukaryotic mRNAs have longer half-lives, ranging from 10 to 20 minutes in yeast to several hours in mammalian cells. Most eukaryotic mRNA degradation is deadenylation-dependent:

  • Deadenylation: Degradation is initiated by the gradual removal of the poly(A) tail by deadenylase complexes, such as CCR4-NOT or PAN2-PAN3.
  • Once the poly(A) tail is shortened to a critical threshold (10 to 12 nucleotides), the transcript is degraded via one of two major pathways:
    • Decapping and 5′ -> 3′ Degradation: The decapping enzyme complex (Dcp1/Dcp2) cleaves the 5′-cap, releasing m7GDP and leaving a 5′-monophosphate on the transcript. This 5′ end is then rapidly degraded by the 5′ → 3′ exoribonuclease Xrn1.
    • 3′ -> 5′ Exosome Degradation: The deadenylated transcript is degraded from its 3′ end by the exosome complex, a conserved ring-like complex of 3′ → 5′ exoribonucleases. Any remaining 5′-cap is subsequently cleared by a scavenger decapping enzyme (Dsc1).
Eukaryotic mRNA Degradation Pathways Stable mRNA 5′ [Cap] ====================================== [Poly(A) Tail] 3′ CCR4-NOT removes Poly(A) Deadenylated mRNA 5′ [Cap] ====================================== OH 3′ Decapping (Dcp1/Dcp2) → Xrn1 5′ OH ==================== 3′ Rapid 5′-to-3′ Degradation Exosome Complex (3′-to-5′) 5′ [Cap] =============== 3′ Rapid 3′-to-5′ Degradation

12.3 mRNA Surveillance Quality Control Pathways

Eukaryotic cells possess surveillance networks that identify and destroy aberrant or defective mRNA transcripts before they can be translated into potentially toxic proteins.

Nonsense-Mediated mRNA Decay (NMD)

NMD targets and degrades mRNAs that contain premature translation termination codons (PTCs).

  • The Exon Junction Complex (EJC): During splicing, a multiprotein complex called the Exon Junction Complex (EJC) is deposited on the mRNA transcript approximately 20 to 24 nucleotides upstream of each exon-exon junction.
  • The Spatial Rule: During normal translation, the ribosome translocates along the mRNA and displaces all EJCs from the coding region before reaching the normal stop codon, which is typically located in the final exon.
  • PTC Recognition: If an mRNA contains a premature stop codon upstream of an exon-exon junction, the ribosome stalls at the PTC. Any downstream EJCs that remain attached to the mRNA downstream of the stalled ribosome recruit the NMD factors Upf1, Upf2, and Upf3.
  • Targeting for Degradation: The association of Upf1 with the stalled ribosome and downstream EJCs activates a kinase cascade that targets the transcript for rapid endonucleolytic cleavage, decapping, and degradation.
Nonsense-Mediated Decay (NMD) in Mammals Normal Translation: 5′ [Cap] == [Exon 1] == [Exon 2] ====== [Stop] == [Last Exon] -- [Poly(A)] 3′ (No EJCs left) → Normal Termination Aberrant Translation (with PTC): 5′ [Cap] == [Exon 1] === [UAG (PTC)] === [Exon 2] ====== [Exon 3] -- [Poly(A)] • Ribosome stalls at PTC [UAG]. • Downstream EJCs remain attached and recruit Upf1, Upf2, and Upf3 factors. → NMD Activation: Rapid Endonucleolytic Cleavage & Degradation

Nonstop-Mediated mRNA Decay

Nonstop-mediated decay targets and degrades mRNAs that lack an in-frame stop codon.

  • The Problem: If an mRNA lacks a stop codon, the ribosome translates through the coding sequence and poly(A) tail, translating the poly(A) tail into a poly-lysine tract. The ribosome then stalls when it reaches the very 3′ end of the transcript.
  • The Solution: Ribosome stalling at the 3′ end recruits specific rescue factors that release the stalled ribosome and recruit the exosome complex to rapidly degrade the defective transcript from its 3′ end.

Chapter 13: Cytoplasmic Compartmentalization of mRNA: P-Bodies and Stress Granules

In the cytoplasm, mRNAs are not simply dispersed in solution. Instead, they are partitioned into specialized, membraneless ribonucleoprotein (RNP) granules that act as physical hubs for storage, translation repression, and degradation.

13.1 Processing Bodies (P-Bodies)

P-bodies are dynamic, membraneless cytoplasmic granules that contain enzymes involved in mRNA translation repression and degradation.

  • Key Components: P-bodies contain the decapping enzyme complex (Dcp1/Dcp2), the 5′ → 3′ exoribonuclease Xrn1, the deadenylase complex (Ccr4-Not), translational repressors, and mRNA surveillance proteins.
  • Initiation Factor Exclusion: To prevent active translation within P-bodies, translation initiation factors (such as eIF4G, eIF4A, eIF4B, and the 40S subunit) are excluded from these granules. A notable exception is eIF4E, which can be found in mammalian P-bodies in an inactive, repressed state.
  • Function: P-bodies act as sites for mRNA degradation and temporary storage of translationally repressed transcripts.
Cytoplasmic mRNA Partitioning Active Translation Pool [ Polyribosome Assemblies ] PROCESSING BODIES (P-Bodies) • Decapping (Dcp1/2) • Exonucleases (Xrn1) • Repressors (No Initiation Factors) [ mRNA Decay & Storage ] STRESS GRANULES • Initiation Factors (eIF4E, G, A, B) • 40S Ribosomal Subunit • PABP (No Decay Enzymes) [ Translation Arrest Storage ]

13.2 Stress Granules

Stress granules are dynamic, reversible RNP complexes that assemble in response to stress conditions (such as heat shock, oxidative stress, or viral infection) that inhibit translation initiation.

  • Key Components: In contrast to P-bodies, stress granules contain translation initiation factors (eIF4E, eIF4G, eIF4A, eIF4B, eIF3, and eIF2), poly-A binding protein (PABP), and the 40S ribosomal subunit. They do not contain active mRNA decay enzymes.
  • Function: Stress granules act as protective storage sites for non-translating mRNAs during cell stress. Once the stress condition is resolved, the granules disassemble, releasing the stored mRNAs back into the active translation pool.

13.3 Dynamic Equilibrium and mRNA Exchange

P-bodies, stress granules, and active polyribosomes exist in a continuous, dynamic equilibrium. mRNAs can be rapidly partitioned between these compartments based on the translational status of the cell. Under stress conditions, mRNAs are shifted from active polyribosomes into stress granules and P-bodies. When translational blocks are removed, mRNAs are released back into the cytosol to resume translation.

Chapter 14: Solved Textbook and Quantitative Analytical Problems

Problem 1: Intestinal Base Modification Splicing Logic

A researcher isolates an intestinal cell line containing a temperature-sensitive mutation in the gene encoding cytidine deaminase. At the permissive temperature (30°C), the cells secrete both ApoB-100 and ApoB-48. At the restrictive temperature (42°C), the cytidine deaminase enzyme is completely denatured and inactive.

Question: Predict the molecular phenotype of the apolipoprotein B transcripts and the ratio of ApoB-100 to ApoB-48 protein isoforms secreted by these cells at 42°C compared to wild-type cells.

Detailed Solution

  • Enzymatic Activity of Cytidine Deaminase: Cytidine deaminase is the enzyme responsible for the site-specific deamination of cytosine (C) to uracil (U) at nucleotide position 6666 in intestinal apolipoprotein B pre-mRNA. This deamination converts a glutamine codon (5′-CAA-3′) to a stop codon (5′-UAA-3′), resulting in the translation of the truncated ApoB-48 isoform.
  • Impact of the Mutation at the Restrictive Temperature (42°C): At 42°C, the temperature-sensitive cytidine deaminase is inactive. Splicing proceeds normally, but the deamination event at position 6666 cannot take place.
  • Transcript Phenotype: The intestinal apolipoprotein B transcripts remain unedited. Every transcript retains the original 5′-CAA-3′ codon at position 6666.
  • Protein Isoform Ratio: Translation of these unedited transcripts continues past position 6666 until it reaches the normal termination codon at the 3′ end of the transcript. Consequently, the cells synthesize and secrete 100% ApoB-100 protein and 0% ApoB-48 protein. The phenotypic ratio of ApoB-100 to ApoB-48 shifts from a wild-type mixed ratio to an exclusive ApoB-100 phenotype.

Problem 2: Splicing Kinetics and ATP Hydrolysis Analysis

A biochemical assay is set up using purified pre-mRNA transcripts containing a single consensus GU-AG intron. The reaction is incubated with purified spliceosomal snRNPs and auxiliary proteins. In Experiment A, ATP is added to the reaction mixture. In Experiment B, a non-hydrolyzable analogue of ATP (AMP-PNP) is added instead.

Question: Compare the progression of spliceosome assembly and splicing catalysis in Experiment A versus Experiment B.

Detailed Solution

  • Role of ATP in Splicing: Splicing transesterification chemistry is energy-neutral and does not require ATP hydrolysis. However, ATP hydrolysis is required for the conformational rearrangements that occur during spliceosome assembly, including U2 binding, tri-snRNP recruitment, and U1/U4 release.
  • Outcome in Experiment A (with ATP): Spliceosome assembly proceeds normally through the commitment (E), pre-spliceosome (A), pre-catalytic (B1), and activated (B2) complexes to form the catalytic (C) complex. Splicing catalysis proceeds successfully, yielding mature ligated exons and a released lariat intron.
  • Outcome in Experiment B (with non-hydrolyzable AMP-PNP):
    • E Complex Assembly: The commitment (E) complex assemblies normally at the 5′ and 3′ splice sites because E complex formation is ATP-independent.
    • Arrest at the E-to-A Transition: Spliceosome assembly is blocked at the transition from the E complex to the pre-spliceosome (A) complex. This transition requires ATP hydrolysis by an RNA helicase to facilitate the base-pairing of U2 snRNA with the branch point sequence.
    • Catalytic Splicing Outcome: Because the spliceosome cannot transition to the active A complex, no catalytic splicing occurs. The reaction contains only intact, unspliced pre-mRNA.

Problem 3: Quantitative Ribosome Stalling and mRNA Quality Control

A eukaryotic reporter construct is engineered with an open reading frame of 900 nucleotides. A point mutation is introduced at nucleotide position 450, converting a tyrosine codon (5′-UAC-3′) to an amber stop codon (5′-UAG-3′). The gene contains two introns: Intron 1 is located between nucleotides 300 and 350, and Intron 2 is located between nucleotides 600 and 650.

Question: Explain whether this mutant transcript will be targeted by the nonsense-mediated decay (NMD) pathway in mammalian cells, and calculate the distance (in nucleotides) between the premature stop codon and the closest downstream exon-exon junction in the spliced mRNA.

Detailed Solution

Exon-Exon Junction Coordinates in Spliced mRNA:

  • Exon 1: Nucleotides 1 to 299 (299 nt).
  • Intron 1: Nucleotides 300 to 350 (51 nt, spliced out).
  • Exon 2: Nucleotides 351 to 599 (249 nt).
  • Intron 2: Nucleotides 600 to 650 (51 nt, spliced out).
  • Exon 3: Nucleotides 651 to 900 (250 nt).
  • After splicing, the continuous mature mRNA sequence is formed by joining Exons 1, 2, and 3:
    • Spliced mRNA Exon 1 segment: Nucleotides 1 to 299 of spliced mRNA.
    • Exon-Exon Junction 1 (EEJ1): Located at the boundary between nucleotide 299 and 300 of the spliced mRNA transcript.
    • Spliced mRNA Exon 2 segment: Nucleotides 300 to 548 of spliced mRNA (length = 249 nt).
    • Exon-Exon Junction 2 (EEJ2): Located at the boundary between nucleotide 548 and 549 of the spliced mRNA transcript.
    • Spliced mRNA Exon 3 segment: Nucleotides 549 to 798 of spliced mRNA (length = 250 nt).
    • Total spliced mRNA length = 299 + 249 + 250 = 798 nt.

Premature Stop Codon (PTC) Coordinate in Spliced mRNA:

  • The mutation is introduced at position 450 of the unspliced primary transcript.
  • Since position 450 lies within Exon 2 (which spans nucleotides 351 to 599), this mutation is retained in the spliced mRNA.
  • Its position in the spliced mRNA is: Position = 299 (length of Exon 1) + (450 - 350) = 299 + 100 = 399 nt
  • The premature stop codon (5′-UAG-3′) spans nucleotides 399, 400, and 401 of the spliced mRNA.

Distance to the Closest Downstream Exon-Exon Junction:

  • The closest downstream exon-exon junction is EEJ2, which is located at the boundary between nucleotide 548 and 549.
  • The distance from the first nucleotide of the PTC (399) to EEJ2 is: Distance = 548 - 399 = 149 nucleotides

Targeting by the Nonsense-Mediated Decay (NMD) Pathway:

  • The Spatial Rule: In mammalian cells, a premature stop codon targets a transcript for NMD if it is located >50 to 55 nucleotides upstream of an exon-exon junction.
  • Conclusion: Since the premature stop codon is located 149 nucleotides upstream of EEJ2, it satisfies the spatial rule. The stalled ribosome will leave the Exon Junction Complex (EJC) at EEJ2 undisturbed, which will recruit Upf proteins and target the mutant transcript for rapid NMD degradation.

Problem 4: Inhibitor Specificity Matrix of Transcription and Processing

A drug screening assay evaluates three newly developed compounds—Compound X, Compound Y, and Compound Z—for their effects on RNA transcription and processing in human cell extracts:

  • Compound X: Selectively binds to and blocks the pocket of the eukaryotic capping guanylyltransferase.
  • Compound Y: Selectively inhibits the phosphorylation of the serine-5 (Ser5) residues on the CTD heptad repeats of RNA Polymerase II.
  • Compound Z: Selectively blocks the binding of the U1 snRNP to the pre-mRNA transcript.
Question: Compare the specific molecular consequences of treating human cells with each of these three compounds.

Detailed Solution

  • Treatment with Compound X:
    • Target: Blocks eukaryotic capping guanylyltransferase.
    • Consequences: Transcription initiation and elongation proceed normally, and RNA triphosphatase can still remove the terminal γ-phosphate from the 5′ end of transcripts. However, the guanylyltransferase cannot transfer GMP to the 5′ end of the pre-mRNA. The transcripts remain unmethylated at their 5′ end, leaving them highly vulnerable to rapid 5′ → 3′ degradation by nuclear exonucleases.
  • Treatment with Compound Y:
    • Target: Blocks phosphorylation of the Ser5 residues on the CTD of RNA Polymerase II.
    • Consequences: RNA Polymerase II is unable to recruit the dimeric capping enzyme to the transcription complex. This prevents all three steps of the 5′ capping reaction, resulting in un-capped pre-mRNAs. Additionally, because Ser5 phosphorylation is required to recruit transcription initiation and early elongation factors, transcription elongation rates are severely reduced, and splicing of the first intron is inhibited.
  • Treatment with Compound Z:
    • Target: Blocks U1 snRNP binding to the pre-mRNA.
    • Consequences: Transcription, 5′-capping, and 3′-polyadenylation proceed normally. However, because U1 snRNP cannot bind to 5′ splice sites, the commitment (E) complex cannot assemble. This completely inhibits spliceosome-mediated splicing of GU-AG nuclear introns, leading to accumulation of unspliced pre-mRNA transcripts in the nucleus.

In this lesson

LessonStep 11 of 33

Next quizRNA Processing and Post-Transcriptional Regulation
Scroll to Top